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Objective: Pain exacerbated by movement and loading on the joint is the major symptom of osteoar-
thritis (OA), but the mechanisms of chronic pain in this pathology are still poorly understood. Using the
intra-articular (i.a.) injection of collagenase in the knee of rats as a model of OA, we aimed at evaluating
whether injury of sensory neurons may contribute to the development of OA-associated nociception.
Design: OA was induced by i.a. injection of collagenase into the left knee joint of adult male Wistar rats.
Histopathological changes and movement and loading-induced nociception were assessed for 6 weeks. A
time-course analysis of the expression of the neuronal injury markers activating transcription factor-3
(ATF-3) and neuropeptide Y (NPY) and of the neuropeptide SP in the dorsal root ganglion (DRG) was
performed. Gabapentin's effect on nociception was evaluated, as well as the expression of the a2d-1
voltage-gated calcium channel subunit.
Results: Collagenase induced the development of OA-like histopathological changes and of movement-
induced nociception. Altered expression of ATF-3, NPY and SP was observed in the DRG, correlating
with the degree of articular degeneration after 6 weeks of disease progression. Repeated administration
of gabapentin reversed the nociceptive responses 6 weeks after the induction of OA. a2d-1was upre-
gulated in the DRG.
Conclusion: By inducing nociceptive behaviours associated with relevant joint structural changes, the i.a.
injection of collagenase presents itself as a pertinent model for the study of OA pain. The ﬁndings in this
study support the hypothesis that injury of sensory neurons innervating OA joints may be a signiﬁcant
element in the mechanisms of OA-associated pain.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Pain is the most distressing feature of osteoarthritis (OA). Recent
data suggests that OA-associated pain may be partially due to
neuropathic mechanisms, as many patients present clinical fea-
tures characteristic of neuropathic pain1,2. These observations
concur with a possible injury of primary afferents innervating OA: S. Ad~aes, Departamento de
da Faculdade de Medicina da
Herna^ni Monteiro, 4200-319
3654.
ternational. Published by Elsevier Ljoints, and studies in animal models of OA support this hypoth-
esis3e5. An upregulation of neuronal injury markers has been
described for the monoiodoacetate (MIA) model of OA36, but
MIA's mechanism of action raises some concerns when dealing
with nerve injury4,5. Therefore, in the present study we used the
intra-articular (i.a.) injection of collagenase in the rat's knee as a
model of OA.
We have recently shown that the injection of collagenase leads,
after 6 weeks of disease progression, to a set of both histopatho-
logical and nociceptive changes that are consistent with the
development of OA-like alterations7. Collagenase induces the
degeneration of articular cartilage (AC) both by directly digesting
collagen from the extracellular matrix of cartilage8, and as atd. All rights reserved.
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thereby reproducing some of the main features associated with OA
onset and development in humans10e15, and being a clinically
relevant experimental approach to the study of OA-associated pain.
With this study, we aimed at further evaluating if neuronal
injury may be coupled to the development of OA-associated noci-
ception. Hence, the expression of activating transcription factor-3
(ATF-3), a widely accepted neuronal injury marker16, and of neu-
ropeptide Y (NPY), known to increase after peripheral nerve injury
but not inﬂammation17e19, was monitored in primary afferent
neurons innervating OA joints. The expression of the neuropeptide
Substance P (SP) in small dorsal root ganglion (DRG) neurons,
which has been described to increase after peripheral inﬂammation
and to decrease after peripheral nerve injury20, was also evaluated.
The anti-convulsant gabapentin is effective in a variety of
neuropathic pain conditions21, and has shown variable effects in
experimental OA, depending on the model, dose and nociceptive
tests used. Therefore, the effect of gabapentin on nociception was
evaluated by the Knee-Bend and CatWalk tests22, that assess
movement- and loading-associated nociception, thereby repro-
ducing a hallmark of pain in this pathology23. The a2d-1 subunit of
voltage-gated calcium channels is a target of gabapentin24 that has
been shown to be overexpressed in DRG neurons after peripheral
nerve injury25. We therefore evaluated the expression of a2d-1
subunit in control and collagenase-injected animals to determine
whether it was changed after the development of OA, which could
be linked to a possible development of neuronal injury and to an
antinociceptive effect of gabapentin.
With this study we hope to contribute to a better understanding
of the mechanisms of nociception in OA, which in turn may lead a
more effective treatment of pain associated with OA.
Material and methods
Animals
Adult male Wistar rats (230 ± 30 g, Charles River) were housed
with water and food ad libitum, at a constant temperature of 22C
and controlled lighting (12 h light/12 h dark cycle). A total of 73
animals were used in this study: 44 for behavioural testing, histo-
pathology and immunoﬂuorescence and 29 for the pharmacolog-
ical experiments. The experimental unit was a single animal.
Experimental procedures were performed in animal procedure
rooms, and in accordance with the ethical guidelines for the study
of experimental pain in conscious animals26, and the European
Union Directive 2010/63/EU, and were approved by the Ethical
Committee for Health of Hospital de S~ao Jo~ao, Porto, Portugal.
OA induction
Under brief isoﬂurane anaesthesia (5% for induction, 2% for
maintenance), i.a. injections were performed using a Hamilton
syringe with a 26G needle inserted through the patellar ligament
into the left knee joint cavity. Animals received two injections, one
on day 0 and another on day 3, of 25 mL of either sterile saline
(control group) or 500 U of type II collagenase from Clostridium
histolyticum (SigmaeAldrich) dissolved in saline and ﬁltered
through a 0.22 mm membrane7,8. Animals were randomly assigned
to each group before the ﬁrst injection.
Nociceptive behaviour
Animals injected with saline or collagenase (44 animals; n ¼ 20
for saline, n ¼ 24 for collagenase) were divided in groups for sac-
riﬁce at different time-points: 1, 2, 4 and 6 weeks after the ﬁrstinjection (n ¼ 5/group/for saline, n ¼ 6/group/for collagenase).
Movement-induced nociceptionwas evaluated in all animals by the
Knee-Bend and CatWalk tests as previously described in Refs. 7,22.
Brieﬂy, for the Knee-Bend test, the squeaks and/or struggle re-
actions in response to ﬁve alternate ﬂexions and extensions of the
knee joint were scored. The contralateral knee was always tested
ﬁrst, as to avoid increased contralateral scores due to manipulation
of the injected knee. Results were presented as the difference be-
tween the ipsilateral and the contralateral Knee-Bend score. For the
CatWalk test, animals were placed in a platform were a bright
image of the paw print was produced. The signal intensity depen-
ded on the area of the paw in contact with the platform and the
pressure applied. For each hind paw, the total paw print intensity
(mean pixel intensity  number of pixels) was determined,
allowing the comparison of the area/pressure applied by each paw.
Results were expressed as the percentage of the total ipsilateral
paw print intensity (%TIPPI) in the sum of both paw prints. The
CatWalk test was always performed prior to the Knee-Bend to
minimise the effect of manipulating the affected knee on the ani-
mals' gait. Testing was performed blindly, always by the same
experimenter, and always in the morning. Animals were tested on
day 0 and weekly after injection, until each group's endpoint.
Joint swelling
Knee diameters were measured with a manual calliper to infer
joint swelling resulting from i.a. injection of collagenase or saline.
Results are presented as the difference between ipsilateral and
contralateral knee diameters.
Retrograde labelling
To identify the perikarya of knee joint afferents, 5 mL of 2%
Fluorogold (FG) (Fluorochrome) were intra-articularly injected in
the left knee of the animals, 7 days prior to sacriﬁce.
Tissue processing
At 1, 2, 4 and 6 weeks after the ﬁrst injection of saline or of
collagenase, rats were perfused with 4% paraformaldehyde. Their
L3, L4 and L5 DRG were dissected, post-ﬁxed in the same ﬁxative
(4 h) and kept in 30% sucrose with 0.01% sodium azide. DRG were
serially sliced in 12 mm sections using a cryostat, with every tenth
section collected in the same slide. Each DRGwas cut longitudinally
yielding 8e10 sections per slide. The injected knees were dissected,
post-ﬁxed for 72 h and then decalciﬁed, processed as previously
described in Ref. 7, and cut in 10 mm sections in the cryostat.
Histopathology
Knee joint sections were stained with Fast Green and Safranin-O
to evaluate the extent of histopathological lesions. Images were
acquired with an Axioskop-40 microscope equipped with an
AxioCam-MRc5 camera (Carl Zeiss MicroImaging GmbH). Histo-
logical scoring was performed based on the OA Research Society
International (OARSI) recommendations for histological assess-
ment of OA in the rat27 in order to conﬁrm the development of
relevant articular changes. A full analysis of the histological changes
induced by this model was performed previously in Ref. 7. Here, we
focused on the most relevant parameters for this model: total
cartilage degeneration width (TCDW), measured as the percentage
of the total width of the medial tibial plateau (MTP); signiﬁcant
cartilage degeneration width (SCDW), also as a percentage of the
MTP; zonal depth ratio (ZDR) of lesions in zone 2, in the centre of
the MTP, the most severely affected region7; cartilage degeneration
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inﬂammation score (SMIS). These parameters were evaluated as
previously described in Refs. 7,27, except for the TCDW and the
SCDW that here are presented as a percentage.
Immunoﬂuorescence and cell counting
Immunoﬂuorescence reactions were performed in slides con-
taining every tenth section of L3, L4 and L5 DRG of rats sacriﬁced 1,
2, 4 or 6 weeks after collagenase or saline injection, as previously
described in Ref. 7. DRG sections were incubated with either mouse
anti-a2d-1 (1:100, Sigma Aldrich), mouse anti-ATF-3 (1:200,
Abcam), rabbit anti-NPY (1:2000, SigmaeAldrich) or rabbit anti-SP
(1:1000, Peninsula Labs), overnight at room temperature. Second-
ary detection was performed with either Alexa Fluor-568 donkey
anti-rabbit or Alexa Fluor-488 donkey anti-mouse secondary anti-
body (1:1000, 1 h, room temperature, Molecular Probes). Slides
were mounted with Prolong Gold Antifade mounting medium
(Molecular Probes). Negative controls were performed without the
primary antibody. Images were acquired through an AxioCamMRm
with AxioVision 4.6 software (Carl Zeiss MicroImaging GmbH). FG-
backlabelled and a2d-1, ATF-3, NPY and SP immunolabelled cells
were quantiﬁed by counting all neurons and all labelled cells on a
slide containing every tenth section of a DRG (one for each reac-
tion). Total cell numbers were conﬁrmed in Nissl stained sections.
The cross-sectional area of the labelled cells was measured using
AxioVision 4.6. Results were expressed as the percentage of
labelled neurons in L3, L4 and L5 DRG. Since therewas a diminished
FG-backlabelling in collagenase-injected animals, immunoﬂuores-
cence analysis was not restricted to the FG-labelled population and
was performed for the whole neuronal population.
Pharmacological evaluation
The effect of either a single or repeated administration of the
anti-convulsant gabapentin in the behavioural responses of OA
animals was evaluated in different random experimental groups.
For the single administration study, gabapentin (SigmaeAldrich)
was administered per os (p.o), in a 100 mg/mL aqueous solution, in
a ﬁnal dose of 100 mg/kg28 (n ¼ 5). At 1, 2, 4 and 6 weeks after
collagenase injection, behaviour was assessed by the Knee-Bend
and CatWalk tests at 30, 60, 120 and 180 min after administra-
tion, as determined in preliminary experiments. Baseline values of
nociception were determined before drug administration
(t ¼ 0 min). For the repeated administration study (total n ¼ 20),
gabapentin administration started at either 1 or 6 weeks after
collagenase injection (n ¼ 5 per group) and was performed twice a
day, for 5 consecutive days (p.o., 30 mg/mL aqueous solution, ﬁnal
dose of 30 mg/kg/administration). Control animals were subjected
to the same procedures, but received administrations of vehicle
(n ¼ 5 per control group). The ﬁrst administration of vehicle was
also used as control for the acute administration, with behavioural
assessment being performed at 30, 60 and 120 min after adminis-
tration. Baseline values of nociception were determined before
drug administration (day 0). Behavioural testing was performed
daily throughout the administration period, always 1 h after the
ﬁrst administration of gabapentin of the day, when its peak effect is
observed29,30.
Statistical analysis
Results are presented as mean (lower 95% conﬁdence interval of
mean, upper 95% conﬁdence interval of mean). The normality of all
data was assessed by the KolmogoroveSmirnov test. Behavioural
data for movement induced-nociception in control andcollagenase-injected groups was analysed by 2-way Analysis of
Variance (ANOVA), followed by the Bonferroni post-hoc test for
multiple comparisons with multiplicity adjusted P values. For the
histological score, the measured parameters were analysed by 1-
way ANOVA followed by Tukey post-hoc test, and the scored pa-
rameters were analysed by the KruskaleWallis test with Dunn's
post-hoc test. The pharmacological data was analysed by Repeated
measures ANOVA followed by Dunnett's post-hoc test. The Man-
neWhitney test was used for the immunoﬂuorescence data. Pear-
son's test was performed for the correlation analysis between the
nociceptive and histopathological data and the immunoﬂuores-
cence and FG backlabelling data.
Results
Movement-induced nociception
The Knee-Bend [Fig. 1(A)] and CatWalk [Fig. 1(B)] tests were
used to evaluate movement-induced nociception following i.a. in-
jection of saline or collagenase. In both tests, control animals
showed, at all time-points, behavioural responses similar to those
observed before injection. In collagenase-injected animals, the
highest increase in nociception was observed 1 week after the ﬁrst
collagenase injection [Fig. 1(A), (B)]. Knee-Bend scores [Fig. 1(A)]
increased from 0.2 (0.3, 0.7) on day 0 to 12.3 (10.9, 13.6) at week 1
(P < 0.0001), reducing from then on until week 4 and increasing
again at week 6 to 8.5 (6.0, 11.0, P < 0.0001). In the CatWalk test
[Fig. 1(B)], the %TIPPI decreased from 49.7 (48.0, 51.5) on day 0 to
35.6 (30.6, 40.6) at week 1 (P < 0.0001), when the lowest values
were observed. The %TIPPI increased from then on until week 4,
decreasing again at week 6 to 42.0 (38.0, 46.0, P ¼ 0.0352).
Joint swelling
Signs of inﬂammationwere detected after collagenase injection,
denoted by a signiﬁcant increase in the difference between the
ipsilateral and contralateral knee diameter at 1 week [P ¼ 0.0003,
Fig. 1(C)].
Histopathology
Histopathological alterations induced by injection of collage-
nase were assessed to conﬁrm OA development and allow corre-
lation with other data. Brieﬂy, saline-injected control animals
showed nomeasurable knee joint damage [Fig. 1(D)], except for the
synovial membrane inﬂammation that was observable at week 1
(SMIS, Table I). Conversely, collagenase-injected rats developed
histopathological alterations [Fig. 1(E)] that included, after 6 weeks
of OA progression, loss of proteoglycan staining and cell death,
chondrocyte clustering and hypertrophy, tidemark undulation,
extensive cartilage degeneration with areas of marked erosion, and
ﬁssures with areas of exposure of the subchondral bone. The
contralateral knees of collagenase-injected rats showed no alter-
ations. The histopathological score is presented in Table I.
Retrograde labelling
Knee joint afferents were retrogradelly labelled with FG
[Fig. 2(A), (B)]. Control animals showed no signiﬁcant differences in
the percentage of FG-backlabelled cells throughout time [Fig. 3(A)],
with an overall average of 1.39% (1.24, 1.54) backlabelled cells in L3,
L4 and L5 DRG. In collagenase-injected rats, a progressive decrease
of FG backlabelling was observed, reaching statistical signiﬁcance
at week 6 when 0.78% (0.63, 0.94) of DRG neurons were back-
labelled (P ¼ 0.0043).
Fig. 1. Nociceptive behaviour, knee diameter and histopathology. A, B: Nociception associated with movement and loading on the joint was evaluated by the Knee-Bend (A) and
CatWalk (B) tests. Knee-Bend score (A) is presented as the difference between ipsi and contralateral scores of saline-injected control and collagenase injected rats. CatWalk data (B)
is expressed as the %TIPPI. C: Joint swelling was assessed by measuring knee diameters (difference between ipsilateral and contralateral knees). A, B, C: The number of animals per
group at each time-point is indicated below the graphs. Animals were sacriﬁced at different time-points for immunoﬂuorescence studies (1, 2, 4 and 6 weeks; n ¼ 5 for saline, n ¼ 6
for collagenase per time-point). Mean with conﬁdence intervals; 2-way ANOVA followed by Bonferroni post-hoc test. *P < 0.05, ***P < 0.001, multiplicity adjusted P values for
comparisons between groups at each time-point. D, E: Histopathological changes in knee joint sections stained with Fast Green and Safranin O. D: Control animals showed unaltered
AC and subchondral bone (SB). E: Animals injected with collagenase, 6 weeks after injection, show extensive cartilage degeneration and erosion, loss of proteoglycan staining
(arrow), chondrocyte clustering and hypertrophy (arrowhead), areas of exposure of the subchondral bone, and tidemark undulation (*). Scale bar: 50 mm.
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The expression of the neuronal injury markers NPY [Fig. 2(C),
(D)] and ATF-3 [Fig. 2(E), (F)] and of the neuropeptide SP [Fig. 2(G),
(H)] in ipsilateral DRG of control animals remained unchanged
throughout time. In collagenase-injected rats, an increase in NPY-
expressing neurons was observed [Fig. 3(D)], most signiﬁcant at
week 1 (0.07% (0.03, 0.11) in controls, 0.78% (0.12, 1.45) in
collagenase-injected, P¼ 0.0043) andweek 6 (0.08% (0.01, 0.16) in
controls, 0.54% (0.38, 0.70) in collagenase-injected, P ¼ 0.0043).
ATF-3 expression showed a similar proﬁle [Fig. 3(G)] with the most
signiﬁcant increases being found at week 1 (0.21% (0.04, 0.39) in
controls, 0.98% (0.04, 1.99) in collagenase-injected, P ¼ 0.0173)
and week 6 (0.09% (0.04, 0.13) in controls, 1.05% (0.44, 1.66) in
collagenase-injected, P ¼ 0.0043). For SP labelling [Fig. 3(J)],
collagenase-injected animals showed an increase at week 1 (11.0%
(9.9, 12.0) in controls, 12.8% (11.2, 14.4) in collagenase-injected,Table I
Histopathology score. Histopathological assessment of degenerative changes in the media
injection. The following parameters were evaluated: total cartilage degeneration width (T
lesions at zone 2 (at the centre of the MTP); cartilage degeneration score (CDS) at zone
animals' data are shown only for SMIS, the only parameter with measurable changes. Mea
followed by Tukey post-hoc test; scored parameters were analysed by the KruskaleW
collagenase injected and control animals within each time point. Signiﬁcant scores are p
Histopathological score
TCDW SCDW ZDR Z2
1 week 42.5
(20.4, 64.6)
P ¼ 0.0018
11.0
(6.7, 28.7)
P ¼ 0.2809
0.43
(0.09, 0.78
P ¼ 0.0066
6 weeks 83.7
(66.6, 100.8) P < 0.0001
42.2
(29.9, 54.4) P ¼ 0.0005
0.79
(0.65, 0.94
P < 0.0001P ¼ 0.0519). SP expression then signiﬁcantly decreased
throughout time to a value of 9.1% (6.7, 11.4) at week 6 (P ¼ 0.0411).
The cross-sectional area distribution proﬁle for FG, ATF-3, NPY
and SP showed that the most signiﬁcant changes occur in small
DRG neurons. At week 1, no changes in the area proﬁle of FG
backlabelled neurons was observed [Fig. 3(B)]. The increased
expression of NPY [Fig. 3(E)] and ATF-3 [Fig. 3(H)] occurred
throughout the cross-sectional area range but was most signiﬁcant
below 1000 m2. Although the overall overexpression of SP was not
signiﬁcant, the area proﬁle showed that this increase speciﬁcally
affected cells in the cross-sectional area range between 500 and
1000 mm2 [Fig. 3(K)]. At week 6, the decrease in FG backlabelling
was shown to affect only cells with a cross-sectional area below
1000 mm2 [Fig. 3(C)]. NPY overexpression was observed in the
250e1250 mm2 range [Fig. 3(F)] and ATF-3 was also increased in
cells below 1250 mm2 [Fig. 3(I)]. The decrease in SP expression was
most pronounced in cells in the 500e750 mm2 range [Fig. 3(L)]. Nol tibial plateau (MTP) of saline- and collagenase-injected animals 1 and 6 weeks after
CDW); signiﬁcant cartilage degeneration width (SCDW); zonal depth ratio (ZDR) of
2; osteophyte score (OS); synovial membrane inﬂammation score (SMIS). Control
n (95% conﬁdence intervals). Measured parameters were analysed by 1-way ANOVA
allis test with Dunn's post-hoc test. P was determined for comparisons between
resented in bold
CDS Z2 OS SMIS control SMIS collagenase
)
1.3
(0.5, 3.2)
P ¼ 0.3532
0.0
(0.0, 0.0)
P > 0.9999
1.4
(0.5, 3.3)
3.2
(2.7, 3.6)
P ¼ 0.4888
)
2.9
(2.4, 3.4)
P ¼ 0.0053
1.7
(0.1, 3.2)
P ¼ 0.0074
0.0
(0.0, 0.0)
1.7
(0.6, 2.8)
P ¼ 0.0767
Fig. 2. Immunoﬂuorescence labelling. Representative images of FG backlabelling and immunoﬂuorescence. All images were obtained from the L4 DRG, 6 weeks after the ﬁrst saline
(A, C, E, G) or collagenase (B, D, F, H) injection. A, B: FG backlabelled DRG neurons (cytoplasmic labelling in blue) in control (A) and collagenase injected (B) rats. C, D: NPY labelled
DRG neurons (cytoplasmic labelling in red) in control (C) and collagenase injected (D) rats. E, F: ATF-3 labelled DRG neurons (nuclear labelling in green) in control (E) and
collagenase injected (F) rats. G, H: SP labelled neurons (cytoplasmic labelling in red) in the DRG of control (G) and collagenase injected (H) rats. Scale bar: 50 mm.
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Correlation analysis
The correlation analysis between the behavioural data, knee
diameter and histopathological score, and the immunoﬂuorescence
and FG backlabelling are presented in Table II.
Pharmacological evaluation
The effect of gabapentin on movement-induced nociception was
evaluated. All animals showed signiﬁcant nociceptive behaviourbefore drug or vehicle administration. For the single administration
study (Fig. 4), no signiﬁcant effects were observed in either the Knee-
Bend [Fig. 4(A)] or the CatWalk [Fig. 4(B)] tests at any time point.
Vehicle administration had no effect in both tests (data not shown,
previouslypublished inRef.7,31).Gabapentinhadnosedativeeffectas
determined by the normal exploratory behaviour in the CatWalk test.
Repeatedly administered gabapentin (Fig. 5) had no effect at
week 1. A slight decrease in nociception throughout the adminis-
tration period was observed in both groups due to the expected
evolution of the nociceptive pattern [Fig. 5(A), (B)]. Conversely,
gabapentin administration starting at week 6 effectively decreased
OA-induced nociception [Fig. 5(C), (D)]. In the Knee-Bend test
[Fig. 5(C)], while rats receiving vehicle administration maintained a
Fig. 3. Immunoﬂuorescence analysis. Time-course immunoﬂuorescence cell counting analysis and cross-sectional area measurements in L3, L4 and L5 ipsilateral DRG of saline- and
collagenase-injected rats. A: FG backlabelling quantiﬁcation at 1, 2, 4 and 6 weeks. B: FG backlabelling area distribution 1 week after injection. C: FG backlabelling area distribution 6
weeks after injection. D: NPY labelling quantiﬁcation at 1, 2, 4 and 6 weeks. E: NPY labelling area distribution 1 week after injection. F: NPY labelling area distribution 6 weeks after
injection. G: ATF-3 labelling quantiﬁcation at 1, 2, 4 and 6 weeks. H: ATF-3 labelling area distribution 1 week after injection. I: ATF-3 labelling area distribution 6 weeks after
injection. J: SP labelling quantiﬁcation at 1, 2, 4 and 6 weeks. K: SP labelling area distribution 1 week after injection. L: SP labelling area distribution 6 weeks after injection. Data are
presented as the percentage of labelled neurons in L3, L4 and L5 DRG. Mean with conﬁdence intervals. *P < 0.05, **P < 0.01, ***P < 0.001, ManneWhitney test for comparisons
between control and collagenase injected animals within each time point.
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pentin showed a signiﬁcant decrease from day 4 onwards, from a
baseline value of 9.7 (8.3, 11.1) to a value of 6.3 (5.3, 7.4) on day 5
(P¼ 0.0219). In the Catwalk test [Fig. 5(D)] the observed decrease in
OA-induced nociception was also signiﬁcant from day 4 onwards,
with the %TIPPI increasing from a baseline value of 36.4% (31.8,
40.9) to 46.8% (45.8, 47.8) on day 5 (P ¼ 0.0004). The vehicle group
maintained a constant %TIPPI.a2d-1 expression
The voltage-gated calcium channel subunit a2d-1 [Fig. 6(A), (B)]
was overexpressed in the DRG of collagenase-injected rats
[Fig. 6(C)] 6 weeks after injection (4.8% (3.4, 6.2) in controls, 8.4%
(4.6, 12.1) in collagenase-injected, P ¼ 0.0411). The repeated
administration of gabapentin for 5 days had no signiﬁcant effect on
a2d-1 expression [Fig. 6(C)].
Table II
Correlation analysis. Pearson's correlation analysis between the immunoﬂuorescence data and the nociception and histopathology evaluation data from saline and
collagenase-injected animals, 1 and 6 weeks after injection. Signiﬁcant correlations are underlined
vs 1 week 6 weeks
ATF-3 NPY SP FG ATF-3 NPY SP FG
Knee-Bend r 0.4529 0.7070 0.4232 0.05590 0.6521 0.8413 ¡0.7341 ¡0.8180
P 0.1619 0.0150 0.1791 0.8781 0.0570 0.0045 0.0243 0.0070
CatWalk r 0.2778 0.2064 0.6115 0.3110 0.4045 ¡0.7882 0.5540 0.4817
P 0.4081 0.5427 0.0603 0.3817 0.2802 0.0116 0.1217 0.1891
Knee diameter r 0.6776 0.8691 0.1920 0.1242 0.1358 0.1679 0.2220 0.2879
P 0.0220 0.0005 0.5951 0.7325 0.7276 0.6659 0.5659 0.4525
TCDW r 0.2991 0.3818 0.4495 0.4036 0.8016 0.8171 ¡0.8295 ¡0.8169
P 0.3716 0.2465 0.1924 0.2474 0.0094 0.0072 0.0057 0.0072
SCDW r 0.2137 0.1027 0.2798 ¡0.7712 0.9106 0.7965 ¡0.7572 ¡0.7901
P 0.5281 0.7638 0.4336 0.0090 0.0006 0.0102 0.0182 0.0113
ZDR Z2 r 0.07306 0.1822 0.3276 0.5164 0.8769 0.8360 ¡0.7459 ¡0.8281
P 0.8310 0.5917 0.3554 0.1265 0.0019 0.0050 0.0210 0.0032
CDS Z2 r 0.06376 0.1395 0.03216 0.4967 0.8469 0.9210 ¡0.7475 ¡0.8563
P 0.8522 0.6825 0.9297 0.1442 0.0040 0.0004 0.0206 0.0058
OS r _ _ _ _ 0.1251 0.6193 0.5123 0.5688
P 0.7485 0.0753 0.1585 0.1100
SMIS r 0.2597 0.3359 0.3454 0.02680 0.4692 0.6453 0.2034 ¡0.7264
P 0.4406 0.3125 0.3283 0.9414 0.2026 0.0605 0.5997 0.0267
Fig. 4. Acute gabapentin administration. The effect of acute gabapentin administration (100 mg/kg, p.o.) on movement- and loading-induced nociception was assessed by the Knee-
Bend (A) and the CatWalk (B) tests, at 1, 2, 4 and 6 weeks after injection of collagenase. Nociception was assessed on day 0, before the ﬁrst collagenase injection, and then on each
test day before gabapentin administration for determination of baseline values (black circles); the effect of gabapentin was determined 30, 60, 120 and 180 min after administration
(white circles). A single administration of gabapentin was ineffective in both tests on all test days. Meanwith conﬁdence intervals. Repeated measures ANOVA followed by Dunnett's
post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 5. Repeated gabapentin administration. The effect of repeated gabapentin administration on movement- and loading-induced nociception was assessed by the Knee-Bend (A,
C) and the CatWalk (B, D) tests. The effect of gabapentin was evaluated in two different groups of collagenase-injected rats, with administration starting at either 1 (A, B) or 6 weeks
(C, D) after injection. Gabapentin was administered p.o. twice a day, for 5 consecutive days, in a 30 mg/kg dose. Control animals were also injected with collagenase and received
administrations of vehicle. Behavioural testing was performed daily throughout the administration period, always 1 h after the ﬁrst administration of the day. Meanwith conﬁdence
intervals. Repeated measures ANOVA followed by Dunnett's post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001.
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The collagenase model has been predominantly used to study
the mechanisms underlying structural joint damage32e34, but we
have recently validated its applicability for the study of OA-
associated pain7. As shown here, the i.a. injection of collagenase
in the knee of rats induces nociceptive behaviours associated with
movement and loading on the OA joint, mimicking patients' major
complaints23, along with histopathological changes that match the
description of human OA35.
A possible neuropathic component in OA-associated pain has
been proposed in a few studies using the MIA model of OA36, the
most extensively used for the study of OA pain. However, some
concerns regarding the possibility of a direct injuring effect of MIA
have been raised4,5. We therefore re-evaluated the possible occur-
rence of neuronal injury in collagenase-induced OA. We observed
that the expression of neuronal injury markers was upregulated
after collagenase injection, both at an early inﬂammatory phase7,
and at a later phase, when articular degeneration is extensive. We
observed a similar proﬁle for both markers in the MIA model of
OA4, consistent with other studies showing ATF-3 expression both
at early3,5 and late6 time-points after MIA injection. This early
upregulation of ATF-3 and NPY also in the collagenase model sug-
gests that the observed expression of these injury markers in the
MIA model may not be a consequence of an MIA-induced lesion. In
fact, ATF-3 is expressed in a variety of stressed tissues36 and can be
triggered by inﬂammatory mediators such as IL-1 and TNF-a37,
being induced in animal models of articular inﬂammation such as
CFA-38 and collagen-induced arthritis39. The initial upregulation of
ATF-3 can therefore be associated with the early inﬂammatory
reaction induced by collagenase injection7,8,40,41, which is reﬂected
in the increased knee diameter, the increased SMIS at week 1, andin the efﬁcacy of diclofenac at early time points7. A similar mech-
anism may occur in the MIA model.
Articular inﬂammation is known to increase SP expression in
the DRG42. We observed that collagenase-injected animals showed
an overexpression of SP 1 week after collagenase injection,
although it did not reach statistical signiﬁcance. This increase may
be attributed to inﬂammation occurring after the i.a. injection of
collagenase. Even though the increased SP expression did not
correlate signiﬁcantly with the degree of joint swelling, a correla-
tion was found between joint inﬂammation and the expression of
neuronal injury markers 1 week after injection. Although NPY is
described as being expressed in the DRG after nerve lesion17,18 but
not after peripheral inﬂammation18, to our knowledge, no studies
have evaluated NPY expression in articular inﬂammation. This can
be a relevant detail since ATF-3 expression increases after injection
of CFA in the joint38 but not in the skin43. It is therefore possible
that a neuroinﬂammatory milieu generated by collagenase injec-
tion in the joint may trigger the early expression of neuronal injury
markers. The fact that no changes in FG backlabelling are observed
at the ﬁrst week, suggests that there is no injury of nerve endings,
at least none that would interfere with FG uptake and retrograde
transport.
As collagenase-induced OA progresses, articular destruction
becomes severe. After 6 weeks, areas of exposed subchondral bone
are observable, rendering nerve ﬁbres in the bone44 susceptible to
mechanical activation and injury. Interestingly, there is a progres-
sive decrease in FG backlabelling from collagenase-injected joints, a
pattern that had also been observed in the MIA model45, and that
may be attributed to injury of nerve endings that interferes with FG
uptake. In fact, there was a correlation of the FG backlabelling, and
the neuronal injury markers and SP expression data with the
severity of the articular destruction at the sixth week; correlations
Fig. 6. a2d-1 expression in DRG neurons. A, B: Representative images of double
immunoﬂuorescence labelling for a2d-1 in the L4 DRG, 6 weeks after the ﬁrst saline (A)
or collagenase (B) injection. C: Immunoﬂuorescence cell counting analysis for a2d-1
labelling in L3, L4 and L5 ipsilateral DRG of saline- and collagenase-injected rats, 6
weeks after injection, and of 6 weeks collagenase-injected rats after repeated gaba-
pentin administration. The percentage of a2d-1positive neurons is presented. Mean
with conﬁdence intervals. KruskaleWallis test; *P < 0.05.
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iour. The expression of SP also decreases gradually throughout time
to values below those of control animals. It is possible that after the
initial inﬂammation-induced SP overexpression, the development
of neuronal injury associated with OA progression may induce the
decrease in SP expression. SP has been described to decrease in
small DRG neurons after peripheral nerve injury20. This matches
the cross-sectional area proﬁle observed in the present study. Small
DRG neurons were in fact the most affected as the decrease in FG
backlabelling was observed in cells with cross-sectional areas
below 1000 m2. This is the area range of themajority of neurons that
innervate the joint46, and these were also the cells that show the
most marked expression of neuronal injury markers.
These results with the collagenase model of OA further reinforce
the hypothesis that injury of primary afferent neurons may be a key
feature of OA. Comparative gene expression studies, using both
MIA-induced and surgically induced OAmodels, suggested that thepain pathways in OA pain may overlap, at least in part, with
neuropathic pain mechanisms47. Gabapentin has shown to be
effective in neuropathic pain conditions21, and has shown variable
effects in the MIA model of OA depending on the dose and noci-
ceptive tests used. A single 100 mg/kg administration signiﬁcantly
reversed tactile alodynia28, whereas a 30 mg/kg dose was only
effective in tactile alodynia after repeated administration48, but
was effective in reversing differences in weight bearing after an
acute administration3. In the collagenase model of OA, we observed
that a single 100 mg/kg dose of gabapentin was ineffective in
reducing movement and loading-induced nociception. However,
when continually administered over 5 days, twice daily in a 30 mg/
kg dose per administration, gabapentin was effective, particularly
in the Catwalk test, in which the decreased loading on the affected
joint was almost fully reverted. Similar differences between acute
and repeated administration of gabapentin have also been
observed in a model of peripheral neuropathy induced by partial
ligation of the left sciatic nerve29. We had previously shown that, in
collagenase-induced OA, diclofenac was effective during the dis-
ease onset, but ineffective as articular destruction increased7,
indicating an early inﬂammatory reaction that subsides as disease
progresses. An opposite proﬁle is shown for gabapentin, being
effective after 6 weeks of OA development, but not at early time-
points, which may support the hypothesis of neuronal injury
occurrence during the progression of OA. Gabapentin's effect in
neuropathic pain has been linked to its binding to the a2d-1 subunit
of voltage-gated calcium channels24, known to be increased after
peripheral nerve injury25. Here, we showed that the a2d-1 subunit
is also overexpressed in the collagenase model of OA, which may
account for the efﬁcacy of gabapentin in this model. This also points
towards the occurrence of neuronal injury as a consequence of OA
progression.
Although inﬂammation may be associated with the onset and
development of OA pain, neuropathic mechanisms may arise as
disease progresses. This is in agreement with the low efﬁcacy of
current therapeutic approaches mainly based on the use of NSAIDs
and with the fact that many OA patients report neuropathic pain
symptoms1. The use of drugs effective in neuropathic pain condi-
tions may therefore be an alternative or a complement to the
treatment of pain associated with OA.
It should be highlighted that OA is a highly heterogeneous dis-
ease resulting from different onset and development mechanisms.
The use of different animal models is important since they may
reproduce different features of the disease. Similar mechanisms
being observed in different animal models, as is the case with the
collagenase and MIA models, may therefore be a strong indication
of their relevance.Contributions
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